Logo image of BCYC

BICYCLE THERAPEUTICS PLC-ADR (BCYC) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BCYC - US0887861088 - ADR

7.45 USD
+0.02 (+0.27%)
Last: 12/12/2025, 8:15:26 PM
7.4 USD
-0.05 (-0.67%)
Pre-Market: 12/15/2025, 8:00:04 AM
Fundamental Rating

3

BCYC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 529 industry peers in the Biotechnology industry. BCYC has a great financial health rating, but its profitability evaluates not so good. BCYC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BCYC has reported negative net income.
In the past year BCYC has reported a negative cash flow from operations.
In the past 5 years BCYC always reported negative net income.
In the past 5 years BCYC always reported negative operating cash flow.
BCYC Yearly Net Income VS EBIT VS OCF VS FCFBCYC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

BCYC has a better Return On Assets (-32.81%) than 64.65% of its industry peers.
With a decent Return On Equity value of -40.53%, BCYC is doing good in the industry, outperforming 70.32% of the companies in the same industry.
Industry RankSector Rank
ROA -32.81%
ROE -40.53%
ROIC N/A
ROA(3y)-25.15%
ROA(5y)-24.21%
ROE(3y)-37.21%
ROE(5y)-36.87%
ROIC(3y)N/A
ROIC(5y)N/A
BCYC Yearly ROA, ROE, ROICBCYC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

BCYC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCYC Yearly Profit, Operating, Gross MarginsBCYC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

More info and screens

7

2. Health

2.1 Basic Checks

BCYC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BCYC has been increased compared to 1 year ago.
BCYC has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, BCYC has an improved debt to assets ratio.
BCYC Yearly Shares OutstandingBCYC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
BCYC Yearly Total Debt VS Total AssetsBCYC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of 0.35, we must say that BCYC is in the distress zone and has some risk of bankruptcy.
BCYC has a Altman-Z score (0.35) which is in line with its industry peers.
There is no outstanding debt for BCYC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.35
ROIC/WACCN/A
WACC9.26%
BCYC Yearly LT Debt VS Equity VS FCFBCYC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

BCYC has a Current Ratio of 10.66. This indicates that BCYC is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BCYC (10.66) is better than 83.18% of its industry peers.
A Quick Ratio of 10.66 indicates that BCYC has no problem at all paying its short term obligations.
BCYC has a better Quick ratio (10.66) than 83.18% of its industry peers.
Industry RankSector Rank
Current Ratio 10.66
Quick Ratio 10.66
BCYC Yearly Current Assets VS Current LiabilitesBCYC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for BCYC have decreased strongly by -12.16% in the last year.
Looking at the last year, BCYC shows a very negative growth in Revenue. The Revenue has decreased by -23.20% in the last year.
BCYC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.65% yearly.
EPS 1Y (TTM)-12.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.86%
Revenue 1Y (TTM)-23.2%
Revenue growth 3Y44.46%
Revenue growth 5Y20.65%
Sales Q2Q%338.49%

3.2 Future

BCYC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.39% yearly.
BCYC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 54.66% yearly.
EPS Next Y-33.25%
EPS Next 2Y-14%
EPS Next 3Y-6.96%
EPS Next 5Y7.39%
Revenue Next Year-14.29%
Revenue Next 2Y-9.92%
Revenue Next 3Y10.35%
Revenue Next 5Y54.66%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BCYC Yearly Revenue VS EstimatesBCYC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
BCYC Yearly EPS VS EstimatesBCYC Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BCYC. In the last year negative earnings were reported.
Also next year BCYC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCYC Price Earnings VS Forward Price EarningsBCYC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCYC Per share dataBCYC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

A cheap valuation may be justified as BCYC's earnings are expected to decrease with -6.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14%
EPS Next 3Y-6.96%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BCYC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BICYCLE THERAPEUTICS PLC-ADR

NASDAQ:BCYC (12/12/2025, 8:15:26 PM)

Premarket: 7.4 -0.05 (-0.67%)

7.45

+0.02 (+0.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30 2025-10-30/bmo
Earnings (Next)02-23 2026-02-23/amc
Inst Owners78.29%
Inst Owner Change-7.39%
Ins Owners1.37%
Ins Owner Change0.24%
Market Cap516.79M
Revenue(TTM)28.34M
Net Income(TTM)-250.66M
Analysts80
Price Target22.02 (195.57%)
Short Float %3.38%
Short Ratio4.94
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.61%
Min EPS beat(2)-17.46%
Max EPS beat(2)22.68%
EPS beat(4)2
Avg EPS beat(4)2.29%
Min EPS beat(4)-17.46%
Max EPS beat(4)22.68%
EPS beat(8)6
Avg EPS beat(8)13.32%
EPS beat(12)7
Avg EPS beat(12)6.82%
EPS beat(16)7
Avg EPS beat(16)2.32%
Revenue beat(2)1
Avg Revenue beat(2)-5.14%
Min Revenue beat(2)-67.15%
Max Revenue beat(2)56.87%
Revenue beat(4)2
Avg Revenue beat(4)-4.42%
Min Revenue beat(4)-67.15%
Max Revenue beat(4)56.87%
Revenue beat(8)4
Avg Revenue beat(8)20.04%
Revenue beat(12)6
Avg Revenue beat(12)20.69%
Revenue beat(16)7
Avg Revenue beat(16)10.87%
PT rev (1m)-11.6%
PT rev (3m)-11.6%
EPS NQ rev (1m)1.93%
EPS NQ rev (3m)9.98%
EPS NY rev (1m)0.15%
EPS NY rev (3m)7.95%
Revenue NQ rev (1m)5.54%
Revenue NQ rev (3m)-2.63%
Revenue NY rev (1m)0.29%
Revenue NY rev (3m)12.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 18.24
P/FCF N/A
P/OCF N/A
P/B 0.84
P/tB 0.84
EV/EBITDA N/A
EPS(TTM)-3.69
EYN/A
EPS(NY)-3.83
Fwd EYN/A
FCF(TTM)-3.49
FCFYN/A
OCF(TTM)-3.46
OCFYN/A
SpS0.41
BVpS8.92
TBVpS8.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -32.81%
ROE -40.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.15%
ROA(5y)-24.21%
ROE(3y)-37.21%
ROE(5y)-36.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.58%
Cap/Sales 7.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.66
Quick Ratio 10.66
Altman-Z 0.35
F-Score3
WACC9.26%
ROIC/WACCN/A
Cap/Depr(3y)192.2%
Cap/Depr(5y)162.86%
Cap/Sales(3y)48.56%
Cap/Sales(5y)34.92%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.86%
EPS Next Y-33.25%
EPS Next 2Y-14%
EPS Next 3Y-6.96%
EPS Next 5Y7.39%
Revenue 1Y (TTM)-23.2%
Revenue growth 3Y44.46%
Revenue growth 5Y20.65%
Sales Q2Q%338.49%
Revenue Next Year-14.29%
Revenue Next 2Y-9.92%
Revenue Next 3Y10.35%
Revenue Next 5Y54.66%
EBIT growth 1Y-47.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-35.62%
EBIT Next 3Y-3.09%
EBIT Next 5YN/A
FCF growth 1Y-404.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-449.2%
OCF growth 3YN/A
OCF growth 5YN/A

BICYCLE THERAPEUTICS PLC-ADR / BCYC FAQ

What is the fundamental rating for BCYC stock?

ChartMill assigns a fundamental rating of 3 / 10 to BCYC.


What is the valuation status of BICYCLE THERAPEUTICS PLC-ADR (BCYC) stock?

ChartMill assigns a valuation rating of 0 / 10 to BICYCLE THERAPEUTICS PLC-ADR (BCYC). This can be considered as Overvalued.


What is the profitability of BCYC stock?

BICYCLE THERAPEUTICS PLC-ADR (BCYC) has a profitability rating of 1 / 10.